Bendels Michael H K, Costrut Alecsandru M, Schöffel Norman, Brüggmann Dörthe, Groneberg David A
Division of Computational Medicine, The Institute of Occupational, Social and Environmental Medicine, Goethe University, Frankfurt, Germany.
Department of Obstetrics and Gynecology, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.
Oncotarget. 2018 Apr 13;9(28):19640-19649. doi: 10.18632/oncotarget.24716.
The present study aims to elucidate the success concerning gender equality in cancer research in the last decade (from 2008 to 2017) with prostate cancer as the target parameter.
31.7% of all authorships and 36.3% of the first, 32.5% of the co- and 22.6% of the last authorships were held by women. The corresponding female-to-male odds ratio is 1.26 (CI: 1.22-1.30) for first, 1.15 (CI: 1.12-1.18) for co- and 0.59 (CI: 0.57-0.62) for last authorships. The annual growth rates are 0.6% overall and 0.9% for first, 0.2% for co-authorships, and 2.8% for last authorships. Women are slightly underrepresented at prestigious authorships compared to men. The female underrepresentation accentuates in articles with many authors that attract the highest citation rates. Multi-author articles with male key authors are more frequently cited. Men publish more articles compared to women (61.8% male authors are responsible for 68.3% of the authorships) and are overrepresented at productivity levels of more than 1 article per author. Major regional differences were found with best female odds in Sweden, Brazil, and Austria. The prognosis for the next decade forecasts a harmonization of authorship odds.
Prostate cancer research is characterized by a career dichotomy with few women in academic leadership positions and many female early career researchers. This career dichotomy has been narrowed in the last decade and will likely be further reduced in the future.
On the basis of the Gendermetrics Platform, a total of 26,234 articles related to prostate cancer research were analyzed.
本研究旨在以前列腺癌为目标参数，阐明过去十年（2008年至2017年）癌症研究中性别平等方面的成果。
所有作者署名中有31.7%由女性持有，第一作者署名中有36.3%、共同作者署名中有32.5%、最后作者署名中有22.6%由女性持有。第一作者的相应女性与男性优势比为1.26（置信区间：1.22 - 1.30），共同作者为1.15（置信区间：1.12 - 1.18），最后作者为0.59（置信区间：0.57 - 0.62）。年增长率总体为0.6%，第一作者为0.9%，共同作者为0.2%，最后作者为2.8%。与男性相比，在享有声望的作者署名中女性的代表性略低。在具有高引用率的多作者文章中，女性代表性不足的情况更为突出。有男性关键作者的多作者文章被引用的频率更高。与女性相比，男性发表的文章更多（61.8%的男性作者占作者署名的68.3%），并且在每位作者发表超过1篇文章的生产力水平上占比过高。发现存在主要的地区差异，瑞典、巴西和奥地利女性的优势比最佳。对未来十年的预测表明作者署名优势将趋于一致。
前列腺癌研究的特点是职业发展存在二分法，担任学术领导职位的女性较少，而女性早期职业研究人员众多。这种职业二分法在过去十年中已有所缩小，未来可能会进一步缩小。
基于性别计量平台，共分析了26234篇与前列腺癌研究相关的文章。
